Page 98 - Read Online
P. 98

Table 1: Key demographic, clinical, and AI/oncologic associations of the GABA B R, GABA A R, and GlyR-α1 antibodies
                          GABA B R                    GABA A R                    GlyR-α1
           Clinical features  Limbic encephalitis (memory   High serum antibodies concentration:   Axial/limb spasms, rigidity, and myoclonus
                          impairment, hallucination,   rapidly progressive encephalopathy,   (SMS) + brainstem signs (PERM)
                          confusion, behavior changes) with   refractory seizures, and status   Optic neuropathy, seizures, cognitive
                          early and prominent seizuresLess   epilepticusLow serum antibodies   impairment, autonomic disturbance,
                          commonly: cerebellar ataxia,   concentration: seizures, SMS,   respiratory failure, and transverse
                          opsoclonus‑myoclonus, brainstem   opsoclonus‑myoclonus, behavioral   myelitis also reported in isolation or with
                          encephalitis, chorea, myelopathy,   change, psychosis, confusion, chorea,   SMS or PERM
                          peripheral neuropathy, and myopathy  ataxia, hallucinations, and hemiparesis
           Onset          Mostly subacute/acute       Acute/subacute              Subacute > acute > chronic
           Age group      Wide range, children, and adults  Wide range, children, and adults  Wide range, children, and adults
           Gender, male:female 1.3:1                  2:1                         1:1
           Inflammatory CSF*   73%                    40%                         50%, but OCB frequently negative
           MRI            65% abnormal (medial temporal >   High serum antibodies concentration:   < 30% T2/FLAIR abnormalities in
                          extratemporal changes)      100% multifocal temporal    temporal lobes, SC abnormalities rarely
                                                      and extratemporal T2/FLAIR   reported (short, multifocal, and LETM)
                                                      hyperintensities
           EMG            ‑                           ‑                           60% abnormal (continuous motor activity,
                                                                                  stimulus induced motor activity)
           Other coexisting   56% (VGCC, AGNA, GAD‑65,   70% (AChR, NMDAR, GABA , GAD‑65, Rare (GAD‑65, MOG, NMDAR,
                                                                          B
           neural antibodies  VGKC‑complex, NMDAR, ANNA‑1,   VGKC‑complex)        aquaporin‑4, VGKC‑complex)
                          ‑2 and ‑3,CRMP‑5 IgG, amphiphysin,
                          BRSK2)
           Associated tumors   62% (SCLC most common, also   15% (invasive thymoma, Hodgkin   Approximately 10% to date (breast
                          neuroendocrine lung, malignant   lymphoma)              cancer, lymphoma (both Hodgkin and
                          melanoma, esophageal, malignant                         NHL), leukemia, lung cancer, melanoma)
                          melanoma, thymus anaplastic carcinoid)
           Fatalities (%)  36                         20                          < 10
           *Inflammatory CSF includes pleocytosis, high protein, raised IgG index, and/or oligoclonal bands. AChR: acetylcholine receptor; AI: autoimmune; AGNA: anti‑glial
           nuclear autoantibody; ANNA: antineuronal nuclear autoantibody; BRSK2: BR serine/threonine‑protein kinase‑2; CRMP‑5: collapsing response mediator protein 5; CSF:
           cerebrospinal fluid; EEG: electroencephalogram; EMG: electromyography; FLAIR: fluid attenuated inversion recovery; GABA A R: γ‑aminobutyric acid receptor A subunit;
           GABA B R: γ‑aminobutyric acid receptor B subunit; GAD‑65: glutamic acid decarboxylase‑65; GlyR‑α1: glycine receptor alpha‑1 subunit; LETM: longitudinally extensive
           transverse myelitis; MOG: myelin oligodendrocyte glycoprotein; MRI: magnetic resonance imaging; NHL: nonHodgkin lymphoma; NMDAR: N‑methyl‑D‑aspartate receptor;
           OCB: oligoclonal bands; PERM: progressive encephalomyelitis with rigidity and myoclonus; SC: spinal cord; SMS: stiff‑man syndrome; SCLC: small cell lung carcinoma;
           VGCC: voltage‑gated calcium channel; VGKC‑complex: voltage‑gated potassium channel complex
           inhibitory neurons in the CNS, has a complex functional   the synaptic membrane. Antibodies to gephyrin, an
           pathway  that  involves  pre‑  and  post‑synaptic  GlyR   anchoring protein in the postsynaptic GlyR, have been
           interacting with other neurotransmitters (GABA and   described only in a single case to date. [40]
           glutamate), NMDAR, and postsynaptic anchoring
           proteins like gephyrin. Antibodies directed at any   Classic neurologic manifestations associated with GlyR
           of these targets may affect the glycinergic system,   antibodies are progressive encephalomyelitis with
           resulting  in  neurological  dysfunction.   Whether  due   rigidity and myoclonus (PERM) and SMS. [39,41,42]  PERM
                                             [34]
           to strychnine (a GlyR antagonist) poisoning, genetic   and SMS were first described as separate clinical entities,
           mutations of the GlyR gene (hereditary hyperekplexia),   but today these 2 conditions are considered to belong
           or  immune‑mediated  encephalitis,  GlyR  dysfunction   to a continuum of CNS hyperexcitability disorders.
           may be associated with severe muscle spasms, stiffness,   Patients with PERM and SMS share common features
           agitation,  seizures,  myoclonus,  autonomic  instability,   of rigidity, painful spasms, autonomic disturbances,
           and/or respiratory failure. [35,36]                hyperekplexia,  and  myoclonus.  The  widespread
                                                              distribution of hyperexcitability and brainstem
           GlyRs, pentamers of α1‑α4 and β‑subunit proteins, are   involvement classically distinguishes PERM from SMS
           ligand‑gated chloride ion channels,  widely distributed   and associated psychiatric symptoms such as anxiety
           in the CNS.  They are predominantly expressed in   are more commonly observed in SMS patients.  [43‑46]
           the olfactory bulb, retina, hippocampus, brainstem   The  autoimmune  nature  of  these  conditions,  and
           (auditory, visual, vestibular, and sensory nuclei),   specifically the involvement of GlyR antibodies in
           cerebellum, and spinal cord. [37,38]  Glycine binding   some cases was not appreciated until recently. [41,42]
           mediates opening of the GlyR chloride channel, resulting   SMS was initially associated with antibodies to
                                                                                                         [40]
           in  hyperpolarization  of  the  membrane  potential  and   GAD‑65 (60‑70% of cases), [47,48]  gephyrin (1 case),  and
           reduced neuronal excitability. The GlyR antibody targets   amphyiphysin (< 5% cases, in the setting of both small
           the α1 subunit of the postsynaptic GlyR and is associated   cell lung and breast cancers). [48,49]  In 2008, Hutchinson
           with hyperexcitable neurologic disorders [Table 1].    et al. [41]   reported  the  first case  of PERM  with  GlyR
                                                         [39]
           Gephyrin allows multiple GlyR to cluster together on   antibodies. It remains unresolved whether all of these


           Neuroimmunol Neuroinfammation | Volume 3 | March 28, 2016                                        89
   93   94   95   96   97   98   99   100   101   102   103